CureVac N.V. (CVAC)

Virosomes as a carrier delivery system for mRNA or adeno virus vector based vaccine candidates $jnj $mrna $bntx $ctlt $mymx

mRNA based vaccines have proven successful in curbing the global COVID-19 pandemic particularly in higher income countries. Current vaccines are formulated in lipid nanoparticles but require a restrictive cold-chain (-15°C to-60°C) which may be not feasible commercially/ logistically when compared to other subunit vaccines approaches typically stored at 4-8 °C. Virosomes are an alternative carrier system commercialised with good safety and efficacy data for Hepatitis A (Epaxal) and Influenza (Inflexal) vaccines.

Project Context and Objectives:
The aim of this project will be to evaluate the feasibility of incorporating candidate mRNA sequences of various sizes into virosomes through different methods including encapsulation, surface linkage and with linkers. The potency and long-term stability of these virosomes will then be evaluated and also formulated for enhanced stability.

Knowledge gained from this project could offer valuable tools that may also be applied to other virosome-based therapies, such as gene therapies.

Results will be presented at regular meetings with the supervisory team, at conferences and published in peer-reviewed journals.

(VAXX) $2.25 ..Potential BEST Vaccine for Covid Prevention with final Phase 3 results in early Q4 and a Alzheimer Vaccine which is Phase 2b ready = this could be the biggest opp of ALL Covid stocks ...GLTA
"The Phase 3 heterologous boost study evaluating UB-612 against COVID-19 in subjects who have received primary immunization from mRNA, adenovirus vector, or inactivated viral vaccines is ongoing. Vaxxinity expects a topline readout in the second half of 2022, and if successful, these data will support global marketing authorization applications."

####